Oramed Pharmaceuticals has announced that it has received a new patent for its oral diabetes treatment. The patent covers oral pharmaceutical compositions comprising insulin in combination with glucagon-like peptide 1 (GLP-1).
Oramed aims to change the treatment of diabetes with its ORMD-0801 oral insulin capsule. The capsule is currently under evaluation in two pivotal Phase 3 trials. The company recently inked a deal to commercialize the oral insulin treatment in the Republic of Korea.
To read more, CLICK HERE.